PAVmed Inc. is a diversified commercial-stage medical technology company operating in the medical device, diagnostics, and digital health sectors. Its businesses include Veris Health, which is focused on cancer-care remote patient monitoring, and Lucid Diagnostics, a cancer-prevention diagnostics company that markets the EsoGuard Esophageal DNA Test and EsoCheck Esophageal Cell Collection Device.
For the first quarter ended March 31, 2026, PAVmed reported revenue of $22,000, compared with $8,000 in the prior-year quarter. The company’s operating expenses were $8.1 million, including general and administrative expenses of $6.4 million and research and development expenses of $1.4 million.
PAVmed reported a GAAP net loss attributable to common stockholders of approximately $7.0 million, or $(4.42) per diluted share. The company’s non-GAAP adjusted net loss was approximately $1.9 million, or $(1.17) per share.